Cargando…

Pharmacoeconomics - Determiniation of the Cost-Effectiveness of Helicobacter Pylori Eradication

Detalles Bibliográficos
Autor principal:	Curtiss, Frederic R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2003
Materias:	Editorial Subjects In This Issue
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437290/ https://www.ncbi.nlm.nih.gov/pubmed/14613444 http://dx.doi.org/10.18553/jmcp.2003.9.5.451

Ejemplares similares

Formulary Management Methods and Pharmacoeconomics
por: Curtiss, Frederic R.
Publicado: (2003)

Pharmacoeconomic Modeling of Drug Therapies for Multiple Sclerosis - Are We Building Houses on Sand?
por: Curtiss, Frederic R.
Publicado: (2007)

Reducing the Risk of Fractures - The Options Narrow for Cost-Effective Therapeutic Alternatives
por: Curtiss, Frederic R.
Publicado: (2004)

Heartburn in Consumer-Directed Health Care and the Cost Outcomes of Therapeutic Maximum Allowable Cost
por: Curtiss, Frederic R.
Publicado: (2006)

Effects of Physician Report Cards, Knowledge of Drug Prices, and Financial Incentives in Prescription Drug Costs
por: Curtiss, Frederic R.
Publicado: (2003)

Which Triptan? - Opportunity for Same or Better Outcomes at Lower Cost
por: Curtiss, Frederic R.
Publicado: (2004)

Clinical, Service, and Cost Outcomes of Computerized Prescription Order Entry
por: Curtiss, Frederic R.
Publicado: (2005)

David and Goliath - Employer Takes on Health Care Cost Management
por: Curtiss, Frederic R.
Publicado: (2004)

Contractual Arrangements Between HMOs and Medical Groups to Manage Drug Costs
por: Curtiss, Frederic R.
Publicado: (2003)

Clinical, Service, and Cost Outcomes of Drug Coverage Edits and Quanitity Limits
por: Curtiss, Frederic R.
Publicado: (2003)

Comparison of efficacy and pharmacoeconomics of two Helicobacter pylori eradication regimens in peptic ulcer disease
por: Kubra Hussaini, Syeda Zaineb, et al.
Publicado: (2018)

Does Member Cost Sharing Pose a Threat to Desirable Patient Outcomes?
por: Curtiss, Frederic R.
Publicado: (2004)

Finding the Truth About Health Care Cost Drivers - Price Versus Utilization Factors
por: Curtiss, Frederic R.
Publicado: (2003)

Pressure on Pharmacy Benefit Managers for Disclosure and Demonstration of Value - Rebates and Drug Benegit Cost Savings
por: Curtiss, Frederic R.
Publicado: (2003)

Value for Money in Disease Management of Acute Coronary Syndrome - The Price of Aspirin to Reduce the Costs of ACS
por: Curtiss, Frederic R.
Publicado: (2005)

PandT Committees - Black Boxes Versus AMCP Format, and What Is the True Cost and Value of Pimecrolimus
por: Curtiss, Frederic R.
Publicado: (2005)

It's Only a Pharmacoeconomic Model--Believe It or Not
por: Fairman, Kathleen A., et al.
Publicado: (2008)

Recent advances in Helicobacter pylori eradication
por: Niv, Yaron, et al.
Publicado: (2015)

Unraveling the Effects of Tier-Copayment Drug Benefit Designs
por: Curtiss, Frederic R.
Publicado: (2003)

Evidence-Based Medicine: Are SSRIs More Effective Than Placebo and What Length of Therapy is Enough?
por: Curtiss, Frederic R.
Publicado: (2005)

Effective Integration of Medical and Pharmacy Claims to Better Protect Patient Safety - A Long Road Yet to Travel
por: Curtiss, Frederic R.
Publicado: (2007)

Strategies for Helicobacter pylori eradication in the year 2020
por: Pellicano, Rinaldo, et al.
Publicado: (2020)

Role of Tegoprazan in Helicobacter pylori Eradication Therapy
por: Lee, Jin
Publicado: (2022)

Disease Management, Pay-for-Performance, and Clinical Pharmacist Interventions in Diabetes Care
por: Curtiss, Frederic R.
Publicado: (2003)

The Relative Value of Disease Management Programs Versus Drug Manufacturer Rebates
por: Curtiss, Frederic R.
Publicado: (2003)

Preventable Drug-related Morbidity (PDRM)
por: Curtiss, Frederic R.
Publicado: (2003)

ERT, HRT, Raloxifine, Calcitonin, or Bisphosphonates for Osteoporosis
por: Curtiss, Frederic R.
Publicado: (2003)

JMCP Award for Excellence
por: Curtiss, Frederic R.
Publicado: (2003)

Consensus Panel, National Guidelines, and Other Potentially Misleading Terms
por: Curtiss, Frederic R.
Publicado: (2003)

Evidence-based Medicine, Practice Guidelines, and Disease Management
por: Curtiss, Frederic R.
Publicado: (2003)

Hypertension, Prescription Drug Copayments, and Drug Therapy Adherence
por: Curtiss, Frederic R.
Publicado: (2003)

Prescription Drug Expenditures, Financial Burden, and Health Plan Satisfaction Among Medicare Beneficiaries
por: Curtiss, Frederic R.
Publicado: (2003)

Real-World Research in Diabetes Care and Protocols for Patient Privacy
por: Curtiss, Frederic R.
Publicado: (2003)

Clinical Pharmacist Intervention in a Primary Care Medical Group Reduces Financial Losses
por: Curtiss, Frederic R.
Publicado: (2004)

Best Value for Money in Triptans
por: Curtiss, Frederic R.
Publicado: (2005)

Evidence-Based Medicine: Which Drugs Are Truly Contraindicated for Use in Older Adults?
por: Curtiss, Frederic R.
Publicado: (2005)

Step-Therapy Edits for PPIs and COX-2 Drugs - What We Do and Do Not Know
por: Curtiss, Frederic R.
Publicado: (2004)

United States, The Last Venue for Direct-to-Customer Advertising, Props Up the Erectile Dysfunction Market
por: Curtiss, Frederic R.
Publicado: (2005)

COPD - Whose Burden, How Large, and What to Do About It?
por: Curtiss, Frederic R.
Publicado: (2005)

OTC Omeprazole for Your Heartburn - Enormous Value-for-Money Opportunity
por: Curtiss, Frederic R.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_bsh5dmkotj6eetq5aurvoid0rk